A simple CD4+ T cells to FIB-4 ratio for evaluating prognosis of BCLC-B hepatocellular carcinoma: a retrospective cohort study

Yong Zhao†, Ling Xiang Kong†, Feng Shi Feng2, Jiayin Yang1* and Guo Wei2*

Abstract

Introduction: Immunotherapy has become a new therapy for advanced hepatocellular carcinoma (HCC); however, its treatment results are considerably different. CD4+ T cells (CD4+) are the key to immunotherapy, but patients with HCC that have low CD4+ are rarely observed for clinical evidence. Hepatitis B virus-related HCC is often accompanied by cirrhosis and portal hypertension; therefore, CD4+ tend to be relatively low in number. TACE is the standard treatment for Barcelona Clinic Liver Cancer (BCLC)-B HCC, which may further reduce the number of CD4+.

Methods: This retrospective cohort study further reduced CD4+ by including patients with human immunodeficiency virus (HIV) to observe the relationship between CD4+ and Chronic hepatitis B virus (CHB) induced HCC. A total of 170 BCLC-B HCC patients (42 HIV+) were included. Univariate and multivariate analyses, and artificial neural networks (ANNs) were used to evaluate the independent risk factors for the two-year survival.

Results: The statistical analysis of the two-year survival rate showed that the main factors influencing survival were liver function and immune indices, including CD4+, platelet, alanine aminotransferase, aspartate aminotransferase, aspartate aminotransferase-to-platelet ratio index, and fibrosis-4 (FIB-4) (P < 0.05). Compared with that in other indices, in logistic and ANN multivariate analysis, CD4+ / FIB-4 had the highest importance with 0.716 C-statistic and 145.93 cut-off value. In terms of overall survival rate, HIV infection was not a risk factor (P = 0.589); however, CD4+/FIB-4 ≤ 145.93 significantly affected patient prognosis (P = 0.002).

Conclusion: HIV infection does not affect the prognosis of BCLC-B HCC, but CD4+ have a significant predictive value. CD4+ played a vital role in HCC and this deserves the attention from physicians. Further, the CD4+/FIB-4 is a clinically valuable effective prognostic indicator for these patients.

Keywords: Human immunodeficiency virus (HIV), Hepatocellular carcinoma (HCC), Barcelona Clinic Liver Cancer (BCLC), Hepatitis B virus (HBV); Platelet (PLT), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Aspartate aminotransferase-to-platelet ratio index (APRI), Fibrosis-4 (FIB-4) © The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
non-small cell lung cancer [1]. The main representative drugs that act as ICPI include CTLA-4 and PD-1 inhibitors. CTLA-4 is expressed in activated CD4+ and CD8+ T cells, which can prevent activating effector T cells, and its inhibitor can induce T cell activation, promote the activation and proliferation of effector T cells, and enhance the tumor killing ability [2]. PD-1 is a negative regulatory molecule of T cells. The expression level of PD-1 in CD4+ T cell subsets and CD4+ T cells in patients with chronic viral hepatitis is also substantially different from that in healthy individuals, and its effect is also closely related to CD4+ and CD8+ T cells [3]. However, due to individual heterogeneous advanced HCC, even patients within the same subgroup have been reported to have significantly different outcomes to treatment [4].

Chronic hepatitis B virus (CHB) infection is a high-risk factor for HCC, and responsible for 50–80% of HCC cases worldwide [5]. T-lymphocyte failure is significantly associated with hepatitis B virus (HBV) replication level. Absence of CD4+ T cells can impair CD8+ T cell activity and antibody production, while the inability to mount a virus-specific CD8+ T cell response results in a level of circulating HBV that cannot be cleared by antibodies alone [6, 7]. While some reports suggest that CD4+ T cells may be potential prognostic markers and therapeutic targets for HCC treatment [8], other studies found no correlation between CD4+ T cells and HCC progression [9, 10]. Due to all the above, the relationship between CHB-induced HCC and CD4+ T cells requires clinical evidence.

As cirrhosis mediates the causal pathway to HCC, patients with CHB-induced HCC often have a certain degree of sclerosis and portal hypertension, and their CD4+ T cells levels are often lower than normal. Circulating and liver-infiltrating CD4+ cytotoxic T lymphocytes (CTLs) are significantly increased in patients with HCC at an early disease stage, but decreased in progressive stages [8]. After TACE treatment, the proportion of CD4+ T cells further decreases [11]. Patients with HIV have also low peripheral blood CD4+ T cells counts. Therefore, to better observe the CD4+ T cells in these patients, this study was designed particularly for patients with BCLC-B HCC, including some with HIV. Additionally, liver condition is also the most important factor to be considered in the successful implementation of immunotherapy for patients with advanced HCC. Biopsy is the gold standard for understanding the degree of liver fibrosis or damage; however, it has limitations, including invasiveness, complications and non-dynamic observation of fibrosis/cirrhosis. Currently, multiple non-invasive methods based on inexpensive laboratory tests predict liver fibrosis, including the aspartate aminotransferase-platelet index (APRI) and the fibrosis index based on the four factors (FIB-4). After conducting a meta-analysis and comparing the results with those from previous studies, we believe that these two indicators have high accuracy [12]. This study aimed to provide clinical evidence on the relationship between absolute number of CD4+ T cells and CHB-induced HCC, observe whether the prognosis of HCC is related to HIV, and provide reference clinical evidence and useful index for subsequent immunotherapy grouping in the era of immunotherapy.

Methods

Patients

Figure 1 details the study design and patient grouping. Only patients who were included who were 18 years of age or older. To ensure the consistency of baseline data, none of the enrolled patients received any other therapies before surgery. Written informed consent was obtained from all the patients prior to their surgery, and all of patients were voluntary and altruistic in all cases, and were in accordance with the ethical guidelines of the Declaration of Helsinki. HCC was diagnosed and managed according to the European Association for the Study of the Liver guidelines [13], American Association for the Study of Liver Diseases updated practice guidelines [14], and the Barcelona Clinic of Liver Cancer guidelines [15]. They were monitored until September 2021 or until their death, and their medical records were retrospectively reviewed. The end point was the 2 – year survival rate, which was the median survival time according to the BCLC standard [16], and A cumulative meta-analysis showed that TACE increased the proportions of patients that survived 2 years [17]. The cut-off value of AFP is ≥400 ng / ml, which is mainly based on the current research that HCC patients with serum AFP levels ≥400 ng / ml had a distinctly poor diagnosis with the lowest recurrence free survival rates [18]. The preoperative blood sample acquisition and imaging examination were completed 3 days before TACE. All patients underwent regular review with liver function tests, serum AFP and imaging studies. The first-time postoperative follow-up was 3–4-weeks after TACE. The related imaging examination including general abdominal color doppler ultrasound, contrast-enhanced liver ultrasound, CT or MRI, were performed according to clinical needs every one, two or three months. TACE was repeated at 1–2-month intervals, depending on the tumor burden and response.

Liver function

Blood was obtained from the peripheral blood of patients who volunteered to participate in our study, then centrifuged at 2000g for 10 min to obtain the serum. The serum levels of alanine transaminase (ALT), aspartate
transaminase (AST), total bilirubin (TB), albumin and prothrombin time (PT) were detected by an automatic biochemical analyzer (Hitachi, Tokyo, Japan).

Peripheral blood mononuclear cells
PBS-diluted blood samples (1:1) were carefully layered on 2 ml human lymphocyte separation medium (Dakewe, Shenzhen, China). Single-cell suspensions were harvested by gradient centrifugation at 800 g for 30 min. PBMCs were washed twice for further experiments.

Flow cytometry
Flow cytometry was used to detect CD3+, CD4+ and CD8+ cells. The antibodies added were FITC-anti-CD3 (BD Biosciences), phycoerythrin-anti-CD4 (BD Biosciences) and allophycocyanin-Cy7-anti-CD8 (BD Biosciences), and then incubated at 4 °C for 20 min. Following centrifugation at 200 x g for 5 min at room temperature, the PBMCs were resuspended with PBS containing 1% paraformaldehyde for fixation at room temperature, the result data were acquired by flow cytometry on a FACS Canton II (BD Biosciences) and analyzed by FlowJo software.

Statistical analysis
R (version 4.0.5) was used to analyze the relevant data. Overall patient survival was estimated by the Kaplan–Meier method, and differences between two groups were determined by log-rank test. Logistic regression and ANN analysis were used to determine the preoperative independent risk factors or protective factors for the two-year survival of patients after TACE. Categorical data were presented as number (per cent) and compared using Pearson chi-Square, Fisher’s exact test. Continuous variables were expressed as the mean value ± SD and analyzed using t-test and repeated measure analysis of variance. P<0.05 was considered to be statistically significant.

Results
Baseline demographic disease features
The disease and clinical characteristics of the study population are shown in Table 1. The main differences between patients who did not achieve a 2-year survival and those with relatively good prognosis related to liver function and immune indexes, with ALT, AST, APRI, FIB-4 (all P<0.05). In addition, the absolute number of CD4+ T cells showed a significant statistical difference in immune indices (P<0.05). In the same way, we conducted two classifications according to the median of CD4+ T cells (Table 2). The results show that the average value of Prothrombin time in the high CD4+ T cells group was higher than that in the low CD4+ group (14.78±2.97 vs. 13.84±1.75, P=0.013).

Risk factor analysis
Based on ROC curve analysis with a 2-year survival rate as outcome index, we calculated the best cut-off value of the statistically significant factors in Table 1, as shown in Table 3. In the univariate analysis, we
Table 1: Baseline demographic and disease features characteristics

| Variables                              | All included patients |Death (n = 93) | Survival (n = 77) | P     |
|----------------------------------------|-----------------------|---------------|-------------------|-------|
| Non-Liver Function or Immune Related Index |                       |               |                   |       |
| Age (mean ± SD, years)                 | 50.67 ± 9.33          | 49.53 ± 12.06 | 0.501             |
| Male                                   | 75 (80.6%)            | 60 (77.9%)    | 0.662             |
| BMI (mean ± SD, kg/m2)                 | 22.02 ± 2.07          | 21.88 ± 1.91  | 0.651             |
| HB (mean ± SD, g/dL)                   | 127.88 ± 19.63        | 132.5 ± 19.9  | 0.131             |
| CRE (mean ± SD, μmol/L)                | 64.45 ± 16.67         | 65.27 ± 17.62 | 0.756             |
| Maximum tumor diameter (mean ± SD, mm) | 79.8 ± 22.62          | 82.97 ± 24.01 | 0.376             |
| Serum AFP > 400 ng/mL                  | 71 (76.3%)            | 55 (71.4%)    | 0.466             |
| Number of tumor > 2                    | 63 (67.7%)            | 51 (66.2%)    | 0.835             |
| Liver Function Related Marker/Index    |                       |               |                   |       |
| Pt (mean ± SD, 10⁹/L)                  | 124.41 ± 50.52        | 137.21 ± 36.34| 0.065             |
| ALT (mean ± SD, u/L)                   | 40.89 ± 19.13         | 49.99 ± 25.91 | 0.012             |
| AST mean ± SD, u/L                     | 85 ± 45.94            | 65.6 ± 39.31  | 0.010             |
| Alb (mean ± SD, g/L)                   | 39.56 ± 36.7         | 38.79 ± 5.34  | 0.404             |
| PT (mean ± SD, s)                      | 14.17 ± 2.21          | 14.47 ± 2.77  | 0.446             |
| TB (mean ± SD, μmol/L)                 | 17.93 ± 8.01          | 17.25 ± 6.62  | 0.550             |
| Child-Pugh score (mean ± SD)           | 6.09 ± 1.01           | 5.94 ± 0.92   | 0.314             |
| Child-Pugh A                           | 66 (71%)              | 61 (79.2%)    | 0.218             |
| Child-Pugh B                           | 27 (29%)              | 16 (20.8%)    | 0.218             |
| Child-Pugh C                           | –                     | –             | –                 |
| APRI                                    | 1.79 ± 1.1            | 1.27 ± 0.88   | 0.001             |
| FIB-4                                   | 6.27 ± 4.47           | 3.84 ± 2.64   | 0.000             |
| Immune Related Marker/Index            |                       |               |                   |       |
| HIV(-)                                  | 24 (25.8%)            | 18 (23.4%)    | 0.715             |
| WBC (mean ± SD, 10⁹/L)                 | 5.47 ± 1.9            | 5.67 ± 1.61   | 0.475             |
| CD3+ T cells                           | 923.47 ± 269.47       | 997.83 ± 366.96| 0.130             |
| CD4+ T cells                           | 426.08 ± 139.34       | 518.04 ± 242.79| 0.004             |
| CD8+ T cells                           | 399.94 ± 140.93       | 445.37 ± 196.17| 0.091             |
| CD4/CD8                                 | 1.15 ± 0.59           | 1.31 ± 0.71   | 0.129             |
| CD4/APRI                                | 329.17 ± 250.42       | 646.55 ± 764.37| 0.001             |
| CD4/FIB-4                               | 102.23 ± 74.32        | 216.17 ± 232.32| 0.000             |

BMI Body mass index, CRE Creatinine, ALB Albumin, TB Total bilirubin, INR International normalized ratio, MELD Model end-stage liver disease, PLT Platelet, WBC White blood cell, HGB Hemoglobin, HBsAg Hepatitis B surface antigen

processed the continuous variables that did not conform to the Gaussian distribution into binary variables. The results from the univariate analysis revealed significant differences in ALT \( \leq 49 \) U/L, AST \( > 67 \) U/L, PLT \( \leq 114 \times 10^9 / L \), absolute number of CD4+ T cells \( \leq 449 \) /μL, among which the protective factors were ALT, PLT, and CD4+ T cells (Table 4). In terms of indexes, APRI \( > 1.22 \), FIB-4 \( > 5.39 \), CD4 / APRI \( \leq 619.97 \) and CD4 / FIB-4 \( \leq 145.93 \) also showed significant differences. Only the ratio CD4+/FIB-4 showed a significant difference when included in the multivariate analysis by logistic regression together with other factors or indices (Table 5). The results of the multi-factor analysis using an ANN to analyze
the importance of all potential factors are shown in Table 6. Among the factors included, CD4/FIB-4 had the highest importance.

**Table 4** The variables in the univariate analysis for the BCLC-B stage

| Variables | All included patients (n = 1464) | Relative risk (95% CI) | P |
|-----------|----------------------------------|------------------------|---|
| Age (years) | 1.010 (0.982–1.039) | 0.488 |
| Male | 0.534 (0.261–1.091) | 0.085 |
| BMI (kg/m²) | 1.036 (0.890–1.206) | 0.649 |
| Child-Pugh score | 1.177 (0.858–1.615) | 0.312 |
| WBC (10⁹/L) | 0.939 (0.791–1.115) | 0.472 |
| sCr (µmol/L) | 0.997 (0.980–1.015) | 0.754 |
| Alb (g/L) | 1.023 (0.971–1.077) | 0.402 |
| PT (s) | 0.953 (0.843–1.078) | 0.444 |
| TB (µmol/L) >2ULN | 1.954 (0.858–4.451) | 0.111 |
| HB (g/dL) <100g/L | 1.229 (0.411–3.669) | 0.712 |
| ALT (u/L) ≤49 | 0.398 (0.212–0.748) | 0.004 |
| AST (u/L) >67 | 2.246 (1.213–4.160) | 0.010 |
| Plt (10⁹/L) ≤114 | 0.389 (0.207–0.732) | 0.003 |
| Serum AFP (ng/mL) >400 | 1.291 (0.649–2.568) | 0.467 |
| Number of tumor ≥2 | 1.071 (0.563–2.034) | 0.835 |
| Maximum tumor diameter (mm) >80 | 0.816 (0.438–1.521) | 0.523 |
| HIV | 0.877 (0.434–1.772) | 0.715 |
| CD3+ T cells (µL) | 0.999 (0.998–1.000) | 0.134 |
| CD4+ T cells (µL) ≤449 | 0.326 (0.174–0.611) | <0.001 |
| CD8+ T cells (µL) | 0.998 (0.997–1.000) | 0.084 |
| CD4+/CD8+ | 0.676 (0.403–1.135) | 0.138 |
| APRI >1.22 | 2.872 (1.537–5.366) | 0.001 |
| FIB-4 >5.39 | 3.404 (1.697–6.829) | 0.001 |
| CD4/APRI ≤619.97 | 0.108 (0.420–0.278) | <0.001 |
| CD4/FIB-4 ≤145.93 | 0.203 (0.103–0.399) | <0.001 |

**Table 5** Independent variables in the multivariate analysis for 2-year survival

| Variables | Logistic regression | Relative risk (95% CI) | P |
|-----------|---------------------|------------------------|---|
| Child-Pugh score | 0.909 (0.637–1.297) | 0.600 |
| CD4/APRI | 1.000 (0.998–1.002) | 0.666 |
| CD4/FIB-4 | 0.993 (0.987–0.998) | 0.012 |
| AST (u/L) | 1.000 (0.991–1.009) | 0.970 |
| Serum AFP (ng/mL) >400 | 1.283 (0.601–2.739) | 0.519 |
| Maximum tumor diameter (mm) | 0.996 (0.982–1.011) | 0.622 |

**Table 6** Independent variables in the ANN analysis for 2-year survival

| Variables | Importance | Normalized Importance |
|-----------|------------|----------------------|
| CD4+/FIB-4 | 0.159 | 100.0% |
| CD4+/CD8+ | 0.130 | 81.8% |
| CD4+/APRI | 0.095 | 60.0% |
| CD4+ T cells (µL) | 0.082 | 51.4% |
| FIB-4 | 0.053 | 33.1% |
| Plt (10⁹/L) | 0.052 | 32.7% |
| ALT (u/L) | 0.051 | 32.3% |
| CD8+ T cells (µL) | 0.048 | 30.1% |
| CD3+ T cells (µL) | 0.044 | 27.9% |
| APRI | 0.040 | 25.4% |
| PT (s) | 0.039 | 24.7% |
| AST (u/L) | 0.035 | 22.4% |
| HIV | 0.035 | 22.3% |
| Child-Pugh score | 0.032 | 19.9% |
| Serum AFP (ng/mL) >400 | 0.029 | 18.1% |
| Number of tumor >3 | 0.027 | 17.0% |
| TB (µmol/L) | 0.027 | 16.7% |
| Maximum tumor diameter (mm) | 0.024 | 14.9% |

**Patient survival**

Based on whether patients had an HIV infection and a CD4/FIB-4 ratio ≤145.93, we drew the overall survival curve corresponding to the above cut-off value as shown in Figs. 2 and 3. The results showed that the median survival time of the HIV group was 20.03±6.31 months (95% CI 7.67–32.40), and that of the non-HIV group was 21.00±5.81 (95% CI 17.45–24.55). There was no significant difference in the overall survival rate between the two groups (P=0.589). According to CD4/FIB-4 rate ≤145.93 grouping, we found a significantly different (P=0.002) median survival time between the high level [26.00±5.56 (24.91±27.09)], and the low level [16.00±2.75 95% CI (10.61±21.39)] groups.

**Discussion**

Our study results showed that the prognosis in patients with advanced HCC was closely related to the absolute number of CD4+ T cells. In contrast to previous studies, our study specifically focused on BCLC-B stage HCC, which is very frequent in many countries where the early diagnosis rate of HCC is not high [19]. In addition, the population included in previous studies often lacked a population with a significant decline in the number of CD4+ T cells, which was usually within the normal range. In this retrospective cohort study, we followed a study cohort with the lowest number of CD4+ T cells.
By including an HIV-infected population in a special cohort study, we could observe these patients more accurately. We found that CD4+ T cells, rather than HIV infection, had a significant impact on the prognosis of patients with BCLC-B HCC. Through comprehensive statistical analysis, CD4/FIB-4 was proved to be a very effective independent predictor for the prognosis of patients with HCC with a C-statistic of 0.716. This predictor index is composed of the most common clinical test values, and its calculation is simple, and can serve as a clinical reference for regions lacking appropriate laboratory testing conditions and/or clinical data support for in-depth laboratory research.

CD4+ T cells are differently involved in tumor occurrence and development, but mainly through immunosuppression, by Foxp3+ Treg cells and cytotoxic T lymphocytes (Tc), memory T lymphocytes, and T helper lymphocytes (Th) [20, 21]. According to the tumor immune evasion theory, cancer patients may drift between Th1/Th2 and Tc1/Tc2, hence hindering anti-tumor immune function in a variety of malignant tumors [22, 23]. Circulating and liver infiltrating CD4+ CTLs were significantly increased in patients with HCC during early disease stages but decreased in progressive stages. Some studies have revealed that inducing apoptosis of CD4+ T cells can promote HCC development, while rescuing apoptosis of CD4+ T lymphocytes can prevent HCC development [24, 25]. In general, the CD4+/CD8+ ratio is decreased, leading to increased immune tolerance and immunosuppression [26]. An association between CD4/CD8 ratio < 0.4 and prominent T cell activation and senescence was reported in patients with CD4+ T cell counts <500/mm³ [27]. However, several studies have reported no correlation between CD4+ T cell levels and HCC progression [9–11]. Although positively correlated with elevated AFP and poor tumor differentiation, CD4+ tumor infiltrating lymphocytes (TILs) are associated with neither overall survival nor disease-free survival [8, 10]. Overall, the detailed mechanisms by which immune cells predict prognosis remains unclear in HCC. A common feature in these studies is that the number of CD4+ T cells is almost at the normal level, and control of patients with low CD4+ number is lacking. Through the selection of the included patients, we successfully observed the cohort of people with low number of CD4+ T cells, and CD4+ T cells had a considerable impact on the prognosis of patients with advanced HCC.

We are currently experiencing the era of tumor immunotherapy; however, ICPI shows that the prognosis of liver cancer treatment is very different. Elucidating the reasons that cause these differences is one of the most important directions of current research. Sorafenib and TACE are the standard treatment for patients with advanced HCC. After sorafenib treatment, the expression and absolute number of PD-1 positive T cells and T regulatory cells are decreased, but those of bone marrow-derived suppressor cells do not change, while the number of PD-1 positive T cells in circulation are decreased significantly. Compared with patients without significant decline, the overall survival is significantly improved. The improvement in overall survival is also significantly better in patients with higher baseline PD-1 positive T cell levels than in those with lower baseline levels [28]. In contrast, at present, there are few reports on immune cells and the results of TACE treatment-related patients. A latest study shows that TACE not only further reduced the CD4+ or CD4+/CD8+ ratio, but also significantly reduced the mRNA expression level of PD1 [11]. However, due to the inclusion of population, the study did not observe a significant impact on CD4+ T cells. Our study demonstrated that CD4+ T cells were positively correlated with the prognosis of patients with liver cancer. Focusing on changes of CD4+ T cells may provide an important research direction for the research of ICPI treatment.

A recent study based on 35,659 HIV infected people has found that higher HIV RNA and longer duration of HIV infection increases HCC risk independently of traditional HCC risk factors, but not the CD4+ T cell number, which is the strongest evidence to date to support the
contribution of HIV viremia to HCC risk in this group [29]. However, whether HIV or CD4+ T cells increase the risk of HCC is still controversial [30–32]. Since the introduction of HAART, patients with HIV have a life expectancy comparable to that of the general population [33, 34]. Liver disease has now become one of the leading causes of hospitalization and death in patients with HIV, with HCC being the main cause [35–37]. Moreover, HIV-infected individuals have a four-fold higher risk of suffering with HCC than uninfected individuals [38]. However, whether HIV combined with HBV may increase the risk of HCC is still controversial [30–32]. At present, the largest study reported that this may be related to absolute number of CD4+ T cells rather than the HIV infection [29]. However, other studies reported that neither early- (≤2 years) nor long-lasting (>2 years) HIV suppression decreased HCC risk [39–42]. As for HCC prognosis, in HIV-infected patients, the 5-year

![Overall Survival Curve](image)

**A** Based on HIV overall survival rate. **B** Based on CD4/FIB-4 overall survival rate.
study, we believe that clinicians should pay more attention to the prognostic impact of immune cells on CHB BCLC-B HCC.

Prospects and limitations
The retrospective design should be acknowledged as a limitation of our study, while the single-center data source limits its scope. Whether our results can be generalized requires further multicenter verification. There were 170 patients with CHB undergoing TACE in the BCLC-B stage, while only 42 HIV-infected patients were included in the analysis; however, to our knowledge, this study is the largest case-control study of survival outcomes of BCLC-B stage patients with HIV who underwent TACE.

Conclusion
Our study shows that the CD4+ T cells number is also significantly correlated with the prognosis of patients with BCLC-B stage, making the immune status of patients with advanced HCC worthy of clinical attention. In our study, liver function and absolute number of CD4+ T cells were the two main aspects affecting patient prognosis, which gradually deteriorate with the aggravation of CHB HCC. Therefore, we suggest that patients with BCLC-B HCC should be treated with TACE as soon as possible. HBV and HIV infections are mainly found in underdeveloped areas, where clinicians can only detect basic common clinical indicators. The CD4/FIB-4 prediction index comprises the most common clinical test values and is easy to calculate. Thus, it can serve as a clinical reference for areas lacking laboratory testing conditions and as clinical data support for future laboratory research. This information may facilitate the development of novel strategies for the early prevention and immunotherapy for patients with HCC by targeting the CD4+ T cells.

Acknowledgements
Not applicable.

Statement
All methods were carried out in accordance with relevant guidelines and regulations under ethics approval and consent to participate section.

Authors’ contributions
LK, GW, YZ, SF and JY designed the study; YZ, LK performed the research and collected the data; LK, YZ, SF, GW analyzed and interpreted the data; YZ, LK wrote the first draft of the manuscript; All authors edited the manuscript and approved the final draft; The acquisition of funding is from JY and GW.

Funding
Cancer Project of Chengdu High-Tech Medical Association (202004), Sichuan Science and Technology Planning Project (2019YFS0204), Hengrui Scientific Research Project of Sichuan Medical Association (0221HRS8).
Availability of data and materials
All related data in this study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The protocol was approved by the Ethics Committee of the West China Hospital of Sichuan University and written informed consent was obtained from all patients for their data to be used in this research. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 23 November 2021 Accepted: 21 March 2022
Published online: 23 March 2022

References
1. Biglow L, Ashraf S, Alsharedi M. Checkpoint inhibitors: literature review of new treatments for hepatocellular carcinoma. Stem Cell Invest. 2021;8:22.
2. Jain N, Nguyen H, Chambers C, Kang J. Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multigang autoreactivity. Proc Natl Acad Sci U S A. 2010;107(4):1524–8.
3. H, Y, C, MC. Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1. Front Immunol. 2021;12:806043.
4. Zhang Y, Lu L, He Z, Xu Z, Xiang Z, Nie RC, et al. C-Reactive Protein Levels Predict Responses to PD-1 Inhibitors in Hepatocellular Carcinoma Patients. Front Immunol. 2022;13:808101.
5. Chen Y, Tian Z. HBV-Induced Immune Imbalance in the Development of HCC. Front Immunol. 2019;10:2048.
6. Kalamis SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med. 1998;188(12):2199–204.
7. You J, Sipilung H, Geater A, Chongsuvivatwong V, Zhuang L, Chen HY, et al. Effect of viral load on T-lymphocyte failure in patients with chronic hepatitis B. World J Gastroenterol. 2008;14(7):1112–9.
8. Fu J, Zhang Z, Zhou L, Qi Z, Xing S, Lu J, et al. Impairment of CD4+ cytoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. Hepatology. 2013;58(1):139–49.
9. Shirabe K, Motomura T, Muto J, Toshima T, Matono R, Mano Y, et al. Tumor-infiltrating lymphocytes and hepatocellular carcinoma: pathology and clinical management. J Clin Oncol. 2010;15(8):552–8.
10. Gao Q, Qin S, Fan J, Zhou J, Wang XY, Xiao YS, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25(18):2586–93.
11. Guo J, Wang S, Han Y, Jia Z, Wang R. Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma. Oncol Lett. 2022;22(1):554.
12. Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology. 2015;61(1):292–302.
13. Cornberg M, Tacke F, Karlesen TH. Clinical Practice Guidelines of the European Association for the study of the Liver - Advancing methodology but preserving practicability. J Hepatol. 2019;70(1):S1–7.
14. Oberkofler CE, Dukovski P, Stocker R, Schuepbach PA, Stover JF, Clavien PA, et al. Model of end stage liver disease (MELD) score greater than 23 predicts length of stay in the ICU but not mortality in liver transplant recipients. Critical Care (London, England). 2010;14(3):R117.
15. Song P, Cai Y, Tang H, Li C, Huang J. The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines from 2001 to 2017. Biosci Trends. 2017;11(4):389–98.
16. Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;150(4):835–53.
17. Llovet JM, Bruix J. Systematic review of randomized trials for unselectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37(2):429–42.
18. Jeon D, Choi WM, Kim JS, Jung Y, Lee SY, Seo HI, et al. Serum Sorbitol Dehydrogenase as a Novel Prognostic Factor for Hepatocellular Carcinoma after Surgical Resection. Cancers (Basel). 2021;13(23).
19. Akinremiyoju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017;3(12):1683–91.
20. Péguellet I, Milder M, Louis D, Vincent-Salomon A, Dorval T, Piperno-Neumann S, et al. High numbers of differentiated effector CD4 T cells are found in patients with cancer and correlate with clinical response after neoadjuvant therapy of breast cancer. Cancer Res. 2014;74(8):2204–16.
21. Zhang Q, Jia Q, Deng T, Song B, Li L. Heterogeneous expansion of CD4+ tumor-infiltrating T-lymphocytes in clear cell renal cell carcinomas. Biochem Biophys Res Commun. 2015;458(1):70–6.
22. Lang F, Linlin M, Ye T, Yuhai Z. Alterations of dendritic cell subsets and TH1/TH2 cytokines in the peripheral circulation of patients with superficial transitional cell carcinoma of the bladder. J Clin Lab Anal. 2012;26(5):365–71.
23. Podhorecka M, Dmoszyńska A, Rollski J, Wasik E. T type 1/type 2 subsets balance in B-cell chronic lymphocytic leukemia—the three-color flow cytometry analysis. Leuk Res. 2002;26(7):1657–60.
24. Brown ZJ, Fu Q, Ma C, Kruhlak M, Zhang H, Luo J, et al. Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development. Cell Death Dis. 2018;9(6):620.
25. Ma C, Kesavarala AH, Eggert T, Medina-Echezar J, Kleiner DE, Jin P, et al. NAFLD causes selective CD4(+ ) T lymphocyte loss and promotes hepatocarcinogenesis. Nature. 2016;531(7593):253–7.
26. Wang L, Shen Y. Imbalance of circulating T-lymphocyte subpopulation in gastric cancer patients correlated with performance status. Clin Lab. 2013;59(3–4):429–33.
27. Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 2014;10(5):e1004078.
28. Kalathil SG, Lugade AA, Muller A, Iyer R, Thanavala Y. PD-1(+ ) T lymphocyte loss and promotes hepato carcinogenesis. JAMA Oncol. 2021;7(12):1759–66.
29. Iannone GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology. 2013;57(2):492–500.
30. Klein MB, Rockstroh JK, Wittkop L. Effect of coinfection with hepatitis C virus on survival of individuals with HIV-1 infection. Curr Opin HIV AIDS. 2016;11(5):521–6.
31. Klein MB, Rockstroh JK, Wittkop L. Effect of coinfection with hepatitis C virus on survival of individuals with HIV-1 infection. Curr Opin HIV AIDS. 2016;11(5):521–6.
32. Marcon PDS, Tovo CV, Kleimann DA, Fisch P, de Mattos AA. Incidence of hepatocellular carcinoma in patients with chronic liver disease due to hepatitis B or C and coinfected with the human immunodeficiency virus: A retrospective cohort study. World J Gastroenterol. 2018;24(5):613–22.
33. Lohse H, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med. 2007;146(2):87–95.
34. Nakagawa F, May M, Phillips A. Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis. 2013;26(1):17–25.
35. Rosenthal E, Roussillon C, Salmon-Ceron D, Georgeot A, Henard S, Huleux T, et al. Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortalite 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalite 2010 survey. HIV Med. 2015;16(4):230–9.
36. Engels EA, Yanik EL, Wheeler W, Gill MJ, Shiels MS, Dubrow R, et al. Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America. Clin Infect Dis. 2017;65(4):636–43.
37. Silverberg MJ, Lau B, Achenbach CJ, Jing Y, Althoff KN, D’Souza G, et al. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med. 2015;163(7):507–18.
38. Sahasrabuddhe VV, Shiels MS, McGlynn KA, Engels EA. The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States. Cancer. 2012;118(4):6226–33.
39. Kowalkowski MA, Day RS, Du XL, Chan W, Chiao EY. Cumulative HIV viremia and non-AIDS-defining malignancies among a sample of HIV-infected male veterans. J Acquir Immune Defic Syndr. 2014;67(2):204–11.
40. Kramer JR, Kowalkowski MA, Duan Z, Chiao EY. The effect of HIV viral control on the incidence of hepatocellular carcinoma in veterans with hepatitis C and HIV coinfection. J Acquir Immune Defic Syndr. 2015;68(4):456–62.
41. Park LS, Tate JP, Sigel K, Brown ST, Crothers K, Gilbert C, et al. Association of Viral Suppression With Lower AIDS-Defining and Non-AIDS-Defining Cancer Incidence in HIV-Infected Veterans: A Prospective Cohort Study. Ann Intern Med. 2018;169(2):87–96.
42. Kong L, Wei G, Lv T, Jiang L, Yang J, Zhao Y, et al. Outcome of TACE treatment in HIV infected patients with hepatocellular carcinoma. Sci Rep. 2021;11(1):696.
43. Berretta M, Garfisi E, Cacopardo B, Cappellani A, Guaraldi G, Cocchi S, et al. Hepatocellular carcinoma in HIV-infected patients: check early, treat hard. Oncologist. 2011;16(9):1258–69.
44. Gelu-Simeon M, Lewin M, Ostos M, Bayan T, Beso Delgado M, Teicher E, et al. Prognostic factors of survival in HIV/HCV co-infected patients with hepatocellular carcinoma: The CARCINOVC Cohort. Liver Int. 2019;39(1):136–46.
45. Lee HW, Ahn SH. Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients. World J Gastroenterol. 2016;22(37):8314–21.
46. Pinato DJ, Sharma R, Citti C, Platt H, Ventura-Cots M. The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma. Aliment Pharmacol Ther. 2018;47(1):95–103.
47. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Clin Liver Dis (Hoboken). 2018;12(1):33–4.
48. Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol. 2019;25(2):93–159.
49. EASL. 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98.
50. Yang L, Wang Q, Cui T, Huang J, Jin H. Reporting and Performance of Hepatocellular Carcinoma Risk-Prediction Models: Based on TRIPOD Statement and Meta-Analysis. Can J Gastroenterol Hepatol. 2021;2021:9996358.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.